REVENUE MEMORANDUM CIRCULAR NO. 128-2022 issued on September 7, 2022 notifies the loss of one (1) set of used/filled-up but unissued BIR Form No. 2313-R – Electronic Certification Authorizing Registration for transactions involving transfer of real

REVENUE MEMORANDUM CIRCULAR NO. 127-2022 issued on September 7, 2022 lifts and removes, effective immediately, the suspension and prohibition under Revenue Memorandum Circular No. 77-2022 on the following:         a. All field audit and

REVENUE MEMORANDUM CIRCULAR NO. 126-2022 issued on September 6, 2022 circularizes the Consolidated Price of Sugar at Millsite for the month of July 2022 contained in Operations Memorandum (OM) Nos. 58-2022, 59-2022, 62-2022, 63-2022 and 65-2022. 

REVENUE MEMORANDUM CIRCULAR NO. 125-2022 issued on September 6, 2022 publishes the August 17, 2022 letter from Food and Drug Administration (FDA) Director General Samuel A. Zacate, endorsing updates to the “List of VAT-Exempt Medicines” under

REVENUE MEMORANDUM CIRCULAR NO. 124-2022 issued on September 1, 2022 publishes the August 15, 2022 letter from Food and Drug Administration (FDA) Director General Samuel A. Zacate endorsing updates to the “List of VAT-Exempt Medicines” under

REVENUE MEMORANDUM CIRCULAR NO. 123-2022 issued on August 31, 2022 clarifies the provisions of Revenue Regulations (RR) No. 6-2022 relative to the removal of the five (5) – year validity period on receipts/invoices, which shall take

REVENUE MEMORANDUM CIRCULAR NO. 122-2022 issued on August 22, 2022 prescribes the guidelines in updating of registration information record of taxpayers who will enroll in the Bureau’s Online Registration and Update System (ORUS).       

REVENUE MEMORANDUM CIRCULAR NO. 121-2022 issued on August 22, 2022 prescribes the guidelines on the lifting of suspension of field audit and operations on all outstanding Letters of Authority/Audit Notices, and Letter Notices pursuant to Revenue

REVENUE MEMORANDUM CIRCULAR NO. 120-2022 issued on August 18, 2022 prescribes additional guidelines and procedures on the manner of payment of penalty relative to violations incurred by Registered Business Enterprises (RBEs) in the Information Technology-Business Process

REVENUE MEMORANDUM CIRCULAR NO. 119-2022 issued on August 8, 2022 publishes the July 20, 2022 letter from Food and Drug Administration (FDA) OIC-Director General Oscar G. Gutierrez, Jr. endorsing updates to the “List of VAT-Exempt Medicines”